Literature DB >> 22102385

The retrospective cohort study for survival rate in patients with advanced hepatocellular carcinoma receiving radiotherapy or palliative care.

Hyuk Soo Eun1, Min Jung Kim, Hye Jin Kim, Kwang Hun Ko, Hee Seok Moon, Eaum Seok Lee, Seok Hyun Kim, Heon Young Lee, Byung Seok Lee.   

Abstract

BACKGROUND/AIMS: This study was conducted to investigate the assessment of treatment efficacy of radiotherapy (RT) and other therapeutic modalities compared with palliative care only for treatment with advanced hepatocellular carcinoma (HCC).
METHODS: From 2002 to 2010, based on the case of 47 patients with advanced HCC, we have investigated each patients' Child-Pugh's class, ECOG performance, serum level of alpha fetoprotein and other baseline characteristics that is considered to be predictive variables and values for prognosis of HCC. Out of overall patients, the 29 patients who had received RT were selected for one group and the 18 patients who had received only palliative care were classified for the other. The analysis in survival between the two groups was done to investigate the efficacy of RT.
RESULTS: Under the analysis in survival, the mean survival time of total patients group was revealed between 30.1 months and 45.9 months in RT group, while it was 4.8 months in palliative care group, respectively. In the univariate analysis for overall patients, there were significant factors which affected survival rate like as follows: ECOG performance, Child-Pugh's class, the tumor size, the type of tumor, alpha fetoprotein, transarterial chemoembolization, and RT. The regressive analysis in multivariate Cox for total patients. No treatment under radiotherapy and high level of Child-Pugh's class grade were independent predictors of worse overall survival rate in patients. In contrast, for the subset analysis of the twenty-nine patients treated with radiotherapy, the higher serum level of alpha fetoprotein was an independent predictors of worse overall survival rate in patients.
CONCLUSIONS: We found that the survival of patients with advanced HCC was better with radiotherapy than with palliative care. Therefore, radiotherapy could be a good option for in patients with advanced HCC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22102385      PMCID: PMC3304653          DOI: 10.3350/kjhep.2011.17.3.189

Source DB:  PubMed          Journal:  Korean J Hepatol        ISSN: 1738-222X


  28 in total

1.  The long-term efficacy of combined chemoembolization and local irradiation in the treatment of patients with large hepatocellular carcinoma.

Authors:  Wei-Jian Guo; Er-Xin Yu
Journal:  Hepatogastroenterology       Date:  2003 Mar-Apr

2.  Clinical results and prognostic factors in radiotherapy for unresectable hepatocellular carcinoma: a retrospective study of 158 patients.

Authors:  Jinsil Seong; Hee Chul Park; Kwang Hyub Han; Chae Yoon Chon
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-02-01       Impact factor: 7.038

3.  Prognostic factors for survival in patients with compensated cirrhosis and small hepatocellular carcinoma after percutaneous ethanol injection therapy.

Authors:  M Pompili; G L Rapaccini; M Covino; G Pignataro; E Caturelli; D A Siena; M R Villani; A Cedrone; G Gasbarrini
Journal:  Cancer       Date:  2001-07-01       Impact factor: 6.860

4.  Cirrhosis and primary cancer of the liver. Comparative study in Tokyo and Cincinnati.

Authors:  W Mori
Journal:  Cancer       Date:  1967-05       Impact factor: 6.860

5.  Toxicity and response criteria of the Eastern Cooperative Oncology Group.

Authors:  M M Oken; R H Creech; D C Tormey; J Horton; T E Davis; E T McFadden; P P Carbone
Journal:  Am J Clin Oncol       Date:  1982-12       Impact factor: 2.339

6.  Growth and spread of hepatocellular carcinoma. A review of 240 consecutive autopsy cases.

Authors:  K Yuki; S Hirohashi; M Sakamoto; T Kanai; Y Shimosato
Journal:  Cancer       Date:  1990-11-15       Impact factor: 6.860

7.  Treatment of cancers involving the liver and porta hepatis with external beam irradiation and intraarterial hepatic fluorodeoxyuridine.

Authors:  T S Lawrence; L M Dworzanin; S C Walker-Andrews; J C Andrews; R K Ten Haken; I S Wollner; A S Lichter; W D Ensminger
Journal:  Int J Radiat Oncol Biol Phys       Date:  1991-03       Impact factor: 7.038

8.  [Practice guidelines for management of hepatocellular carcinoma 2009].

Authors: 
Journal:  Korean J Hepatol       Date:  2009-09

Review 9.  Treatment of small hepatocellular carcinomas.

Authors:  G M Dusheiko; K E Hobbs; R Dick; A K Burroughs
Journal:  Lancet       Date:  1992-08-01       Impact factor: 79.321

10.  Prospective trial of combined transcatheter arterial chemoembolization and three-dimensional conformal radiotherapy for portal vein tumor thrombus in patients with unresectable hepatocellular carcinoma.

Authors:  Kazunari Yamada; Kenta Izaki; Koji Sugimoto; Hiroshi Mayahara; Yoshitaka Morita; Eisaku Yoden; Shinichi Matsumoto; Toshinori Soejima; Kazuro Sugimura
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-09-01       Impact factor: 7.038

View more
  5 in total

1.  2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma.

Authors: 
Journal:  Korean J Radiol       Date:  2015-05-13       Impact factor: 3.500

2.  Consensus for Radiotherapy in Hepatocellular Carcinoma from The 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014): Current Practice and Future Clinical Trials.

Authors:  Hee Chul Park; Jeong Il Yu; Jason Chia-Hsien Cheng; Zhao Chong Zeng; Ji Hong Hong; Michael Lian Chek Wang; Mi Sook Kim; Kwan Hwa Chi; Po-Ching Liang; Rheun-Chuan Lee; Wan-Yee Lau; Kwang Hyub Han; Pierce Kah-Hoe Chow; Jinsil Seong
Journal:  Liver Cancer       Date:  2016-05-03       Impact factor: 11.740

Review 3.  Radiotherapy as valid modality for hepatocellular carcinoma with portal vein tumor thrombosis.

Authors:  Jeong Il Yu; Hee Chul Park
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

Review 4.  Hepatocellular carcinoma: Surgeon's view on latest findings and future perspectives.

Authors:  Jan Erik Slotta; Otto Kollmar; Volker Ellenrieder; B Michael Ghadimi; Kia Homayounfar
Journal:  World J Hepatol       Date:  2015-05-28

5.  2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma.

Authors: 
Journal:  Gut Liver       Date:  2015-05-23       Impact factor: 4.519

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.